NASDAQ:INVA - Innoviva Stock Price, Price Target & More

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Innoviva Inc (NASDAQ:INVA) announced its quarterly earnings results on Thursday, April, 26th. The biotechnology company reported $0.27 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by $0.23. The biotechnology company had revenue of $52.40 million for the quarter, compared to analyst estimates of $71.84 million. Innoviva had a net margin of 64.11% and a negative return on equity of 63.57%. Innoviva's revenue was up 29.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.19 earnings per share. View Innoviva's Earnings History.

Innoviva is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Innoviva.

6 analysts have issued 12 month price objectives for Innoviva's shares. Their predictions range from $8.00 to $16.00. On average, they expect Innoviva's stock price to reach $13.20 in the next twelve months. This suggests that the stock has a possible downside of 7.0%. View Analyst Ratings for Innoviva.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Innoviva include Ionis Pharmaceuticals (IONS), FibroGen (FGEN), Loxo Oncology (LOXO), United Therapeutics (UTHR), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals (GWPH), Madrigal Pharmaceuticals (MDGL), Array Biopharma (ARRY) and OPKO Health (OPK).

Headlines about INVA stock have trended somewhat negative recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Innoviva earned a daily sentiment score of -0.17 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 48.00 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Innoviva's stock is owned by a variety of of retail and institutional investors. Top institutional investors include James Investment Research Inc. (0.20%), Creative Planning (0.04%), Campbell & CO Investment Adviser LLC (0.04%), Municipal Employees Retirement System of Michigan (0.03%) and Fox Run Management L.L.C. (0.02%). Company insiders that own Innoviva stock include Eric Desparbes, George B Abercrombie, Michael W Aguiar, Theodore J Jr Witek and Theodore L Witek Jr. View Institutional Ownership Trends for Innoviva.

INVA stock was sold by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. Company insiders that have sold Innoviva company stock in the last year include Eric Desparbes, George B Abercrombie and Michael W Aguiar. View Insider Buying and Selling for Innoviva.

INVA stock was acquired by a variety of institutional investors in the last quarter, including James Investment Research Inc., Campbell & CO Investment Adviser LLC, Creative Planning and Municipal Employees Retirement System of Michigan. View Insider Buying and Selling for Innoviva.

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of INVA stock can currently be purchased for approximately $14.19.

Innoviva has a market capitalization of $1.44 billion and generates $217.22 million in revenue each year. The biotechnology company earns $134.14 million in net income (profit) each year or $1.17 on an earnings per share basis. Innoviva employs 12 workers across the globe.

Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]